A Director at Clovis Oncology (NASDAQ: CLVS) is Buying Shares

By Carrie Williams

Today, a Director at Clovis Oncology (CLVSResearch Report), Thorlef Spickschen, bought shares of CLVS for $50.23K.

This recent transaction increases Thorlef Spickschen’s holding in the company by 22.79% to a total of $264.7K. In addition to Thorlef Spickschen, one other CLVS executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Clovis Oncology’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $32.98 million and GAAP net loss of $120 million. In comparison, last year the company earned revenue of $23.76 million and had a GAAP net loss of $101 million. The company has a one-year high of $37.27 and a one-year low of $4.98.

Three different firms, including Barclays and RBC Capital, currently also have a Buy rating on the stock.

The insider sentiment on Clovis Oncology has been positive according to 38 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.